4,702 Shares in Novartis AG (NYSE:NVS) Bought by Guerra Advisors Inc

Guerra Advisors Inc acquired a new position in shares of Novartis AG (NYSE:NVS - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 4,702 shares of the company's stock, valued at approximately $524,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Continuum Advisory LLC raised its holdings in shares of Novartis by 10.3% during the fourth quarter. Continuum Advisory LLC now owns 1,021 shares of the company's stock worth $99,000 after acquiring an additional 95 shares during the period. Intergy Private Wealth LLC grew its position in Novartis by 3.9% in the first quarter. Intergy Private Wealth LLC now owns 2,757 shares of the company's stock valued at $307,000 after purchasing an additional 104 shares in the last quarter. Keudell Morrison Wealth Management grew its position in Novartis by 3.8% in the first quarter. Keudell Morrison Wealth Management now owns 2,828 shares of the company's stock valued at $315,000 after purchasing an additional 104 shares in the last quarter. Meridian Wealth Management LLC grew its position in Novartis by 2.6% in the fourth quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company's stock valued at $405,000 after purchasing an additional 106 shares in the last quarter. Finally, D Orazio & Associates Inc. grew its position in Novartis by 2.9% in the first quarter. D Orazio & Associates Inc. now owns 3,795 shares of the company's stock valued at $423,000 after purchasing an additional 108 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Stock Performance

Shares of NVS opened at $120.30 on Friday. The firm has a 50-day moving average of $113.95 and a 200-day moving average of $108.14. Novartis AG has a one year low of $96.06 and a one year high of $120.92. The company has a market cap of $254.12 billion, a PE ratio of 18.80, a price-to-earnings-growth ratio of 1.73 and a beta of 0.59. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.79 and a quick ratio of 0.61.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.16. Novartis had a net margin of 24.70% and a return on equity of 39.44%. The company had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $12.92 billion. During the same quarter last year, the firm posted $1.80 EPS. The company's quarterly revenue was up 11.9% on a year-over-year basis. As a group, equities analysts forecast that Novartis AG will post 8.45 earnings per share for the current year.

Analyst Ratings Changes

Separately, BNP Paribas raised shares of Novartis to a "strong-buy" rating in a research report on Tuesday, April 15th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Novartis currently has a consensus rating of "Hold" and an average price target of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.